Clinical Trials Logo
  1. Home
  2. Becker Muscular Dystrophy
  3. NCT06066580

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy — MESA  

Becker Muscular Dystrophy Clinical Trial

Official title:
An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

Clinical Trial Summary

EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy

Clinical Trial Description

This is an open-label, treatment extension study to evaluate the safety, tolerability, and durability of effect in long-term dosing of sevasemten. EDG-5506-203 MESA will provide continued access to sevasemten treatment to participants with Becker muscular dystrophy who were previously enrolled in EDG-5506-002 ARCH, completed EDG-5506-201 CANYON and GRAND CANYON, or completed EDG-5506-202 DUNE. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06066580
Study type Interventional
Source Edgewise Therapeutics, Inc.
Contact
Status Enrolling by invitation
Phase Phase 2
Start date November 2, 2023
Completion date March 2028
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01168908 - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Phase 2
Recruiting NCT01484678 - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed NCT02147639 - Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy Phase 2/Phase 3
Completed NCT02847975 - Sodium Nitrate to Improve Blood Flow Phase 1
Recruiting NCT02069756 - The Duchenne Registry
Completed NCT04585464 - A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults Phase 1
Recruiting NCT04668716 - Brain Involvement in Dystrophinopathies Part 2
Completed NCT03236662 - (-)- Epicatechin Becker Muscular Dystrophy Phase 2
Completed NCT01350154 - Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients Phase 2
Not yet recruiting NCT06363526 - Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. N/A
Recruiting NCT05409079 - Schulze Muscular Dystrophy Ability Clinical Study N/A
Completed NCT01856868 - Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study) Phase 1/Phase 2
Completed NCT01557400 - Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada Phase 3
Recruiting NCT02109692 - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies N/A
Recruiting NCT03057002 - UTSW HP [13-C] Pyruvate Injection in HCM
Recruiting NCT04583917 - Brain Involvement in Dystrophinopathies Part 1
Withdrawn NCT03076814 - Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy N/A
Completed NCT02207283 - PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy Phase 4
Completed NCT00873782 - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy Phase 1
Not yet recruiting NCT05715957 - Follow-up Study on Female Carriers With DMD Gene Variants